Y-mAbs Therapeutics Inc. (YMAB) Business Metric Overview - Stocknear

Y-mAbs Therapeutics Inc.

NASDAQ: YMAB · Real-Time Price · USD
8.61
0.02 (0.23%)
At close: Sep 15, 2025, 3:59 PM

Y-mAbs Therapeutics Revenue Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
License Revenue 500K 20.9M 1.5M 500K 500K 500K 63.57M 500K 20.75M 15M n/a 1M n/a n/a 2M n/a
License Revenue Growth -97.61% +1293.60% +200.00% 0.00% 0.00% -99.21% +12613.60% -97.59% +38.34% n/a -100.00% n/a n/a -100.00% n/a n/a
Product Revenue 19.02M n/a 47.29M 18.46M 22.8M 19.43M n/a 19.95M n/a 16.45M 12.54M 9.8M 9.6M 8.96M 8.95M 5.38M
Product Revenue Growth n/a n/a +156.18% -19.02% +17.33% n/a n/a n/a n/a +31.19% +27.97% +2.07% +7.06% +0.16% +66.28% n/a

Revenue by Geography

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023
Eastern Asia Revenue 1.73M 1.51M 6.45M 1.01M 3.42M 821K 3.88M
Eastern Asia Revenue Growth +14.73% -76.63% +539.68% -70.48% +315.96% -78.85% n/a
Latin America Revenue 1.01M 2.01M 3.44M 1.27M 1.75M 18.61M 16.07M
Latin America Revenue Growth -49.98% -41.55% +170.75% -27.27% -90.60% +15.79% n/a
Non-Us Revenue 4.71M 7.52M 15.25M 3.13M 7.57M n/a n/a
Non-Us Revenue Growth -37.45% -50.67% +386.94% -58.64% n/a n/a n/a
Non-Us, Other Revenue 15K 165K 38K 852K 332K n/a n/a
Non-Us, Other Revenue Growth -90.91% +334.21% -95.54% +156.63% n/a n/a n/a
United States Revenue 14.32M 13.38M 32.04M 15.33M 15.23M n/a n/a
United States Revenue Growth +7.01% -58.24% +109.03% +0.68% n/a n/a n/a

Operating Expense Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selling, General, and Administrative Revenue 11.31M 13.09M 12.38M 13.61M 17.23M 11.43M 11.13M 10.2M 11.27M 12.25M 10.79M 13.63M 23.08M 13.44M 15.14M 13.99M 13.47M 11.97M 14.63M 11.64M 10.39M 8.13M 6.93M 4.7M 4.14M 3.74M 3.04M 2.68M 1.97M 1.27M 2.65M 766K 760.5K 760.5K
Selling, General, and Administrative Revenue Growth -13.56% +5.75% -9.09% -21.00% +50.83% +2.60% +9.17% -9.49% -8.01% +13.51% -20.79% -40.97% +71.77% -11.23% +8.22% +3.81% +12.57% -18.18% +25.73% +11.96% +27.91% +17.23% +47.50% +13.50% +10.64% +23.21% +13.15% +36.59% +54.12% -51.89% +245.95% +0.72% 0.00% n/a
Research and Development Revenue 11.1M 11.36M 12.21M 11.17M 12.34M 13.27M 13.39M 15.36M 12.05M 13.42M 19.79M 22.45M 26.42M 22.91M 28.76M 23.13M 19.78M 21.58M 24.01M 21M 30.06M 18.62M 16.83M 19.66M 14.49M 12.51M 11.04M 8.73M 8.29M 6.2M 6.63M 3.08M 2.3M 2.3M
Research and Development Revenue Growth -2.24% -7.00% +9.37% -9.50% -6.98% -0.90% -12.83% +27.40% -10.16% -32.19% -11.87% -15.02% +15.31% -20.33% +24.32% +16.95% -8.35% -10.13% +14.31% -30.12% +61.42% +10.67% -14.41% +35.64% +15.85% +13.31% +26.46% +5.28% +33.67% -6.35% +115.38% +33.56% 0.00% n/a